Choroidal neovascularization in an adolescent with RDH12-associated retinal degeneration

Ophthalmic Genet. 2019 Aug;40(4):362-364. doi: 10.1080/13816810.2019.1655770. Epub 2019 Aug 19.

Abstract

Background: Leber congenital amaurosis (LCA) due to RDH12 mutations typically manifests with severe vision loss and panretinal dystrophy. We sought to describe a case of LCA with choroidal neovascularization (CNV) in a 17-year-old patient. Materials and Methods: Case report of a 17-year old with LCA who presented with acute central vision loss of the right eye in the context of a chronic retinal dystrophy. Multimodal retinal imaging including spectral-domain optical coherence tomography and indocyanine green angiography revealed CNV. Results: A 17-year-old boy with previously diagnosed LCA/early-onset retinal dystrophy (EOSRD), with subsequently identified biallelic mutations in RDH12 was found to have type 2 CNV. Patient was treated with intravitreal ranibizumab and exhibited improvement on follow-up exam. Conclusions: Choroidal neovascularization may be a unique occurrence in RDH12-associated retinal dystrophy. Successful treatment of the neovascularization could be accomplished with intravitreal antivasogenic therapy.

Keywords: CNV; EOSRD; LCA; Leber congenital amaurosis; RDH12; choroidal neovascularization; early-onset severe retinal dystrophy.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Alcohol Oxidoreductases / genetics*
  • Angiogenesis Inhibitors / therapeutic use
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / pathology*
  • Humans
  • Male
  • Mutation*
  • Prognosis
  • Ranibizumab / therapeutic use
  • Retinal Degeneration / complications*

Substances

  • Angiogenesis Inhibitors
  • Alcohol Oxidoreductases
  • RDH12 protein, human
  • Ranibizumab